The effects of sorafenib in healthy and cisplatin-treated rats

dc.authorid0000-0002-2778-8059tr
dc.contributor.authorDemirtaş, Levent
dc.contributor.authorGürbüzel, Mehmet
dc.contributor.authorTahirler, Hilal
dc.contributor.authorAkbaş, Emin Murat
dc.contributor.authorKarataş, Özhan
dc.contributor.authorArslan, Yusuf Kemal
dc.date.accessioned2024-03-07T05:19:44Z
dc.date.available2024-03-07T05:19:44Z
dc.date.issued07.10.2023tr
dc.departmentVeteriner Fakültesitr
dc.description.abstractBackground. Sorafenib is a multikinase inhibitor currently used in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Objectives. The literature on this agent is scarce. This study aimed to evaluate the effects of sorafenib when administered to both healthy and cisplatin-induced rats. Materials and methods. The animals were divided into 4 groups: 1) control group that received 0.9% saline intraperitoneally (C); 2) group administered a single dose (7 mg/kg) of cisplatin (Cis); 3) a group administered 20 mg/kg of sorafenib for 7 days (Sor); 4) group administered 20 mg/kg of sorafenib followed by 7 mg/kg of cisplatin for 7 days (Cis+Sor). All animals were sacrificed 7 days after the completion of their treatment arm, and serum and tissue samples were taken. Results. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and interleukin 38 (IL-38) levels were increased in the Sor and Cis+Sor groups compared to the control group. When compared with the control group, serum urea, creatinine, kidney IL-1β, and tumor necrosis factor alpha (TNF-α) levels did not change in the Sor group. When compared to the Cis group, the levels of these parameters decreased in the Cis+Sor group. Conclusions. According to the data obtained, sorafenib caused liver toxicity when given to both healthy and cisplatin-induced rats. While sorafenib did not cause any significant changes in the kidneys when given to healthy rats, it had a healing effect in kidneys after stress induced by cisplatin.tr
dc.identifier.doi10.17219/acem/155216en_US
dc.identifier.pmid36413179en_US
dc.identifier.scopus2-s2.0-85146788442en_US
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://hdl.handle.net/20.500.12418/14808
dc.identifier.wosWOS:000890460800001en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıtr
dc.rightsinfo:eu-repo/semantics/openAccesstr
dc.subjectIL-38, cisplatin, rat, nephrotoxicity, sorafenibtr
dc.titleThe effects of sorafenib in healthy and cisplatin-treated ratsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
449 (1).pdf
Boyut:
2.96 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: